HCLTech launches advanced clinical trials solution with Denodo and AWS

Pallavi Madhiraju- August 6, 2024 0

HCLTech, a prominent global technology company, has unveiled a cutting-edge clinical trials and diagnosis solution developed in collaboration with Denodo, a leader in data management, ... Read More

FDA committee endorses Zevra Therapeutics’ arimoclomol as a treatment for Niemann-Pick Disease Type C

Pallavi Madhiraju- August 3, 2024 0

In a notable advancement for rare disease treatment, Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) has received a significant endorsement from the U.S. Food and Drug Administration ... Read More

$35 million boost for Rona Therapeutics: A new era in RNA medicine begins!

Pallavi Madhiraju- July 20, 2024 0

Rona Therapeutics, a clinical-stage company leading the way in nucleic acid drug research and development, has successfully completed a Series A+ financing round, raising $35 ... Read More

Exscientia takes full ownership of cdk7 inhibitor in oncology breakthrough

Pallavi Madhiraju- July 20, 2024 0

Exscientia plc (Nasdaq: EXAI), a pioneer in AI-driven drug discovery, has reached a strategic milestone by acquiring full ownership of the oral CDK7 inhibitor program ... Read More

Sermonix Pharmaceuticals awarded U.S. patent for lasofoxifene in breast cancer treatment

Pallavi Madhiraju- July 20, 2024 0

Sermonix Pharmaceuticals Inc., a leader in biopharmaceutical innovations, has achieved a significant milestone with the issuance of a new U.S. patent that broadens the application ... Read More

Immutep reports positive Phase IIb results for Eftilagimod Alfa in head and neck cancer treatment

Pallavi Madhiraju- July 14, 2024 0

Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company, has announced encouraging results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial. The ... Read More

Soligenix announces promising results in extended HyBryte treatment study for cutaneous T-cell lymphoma

Pallavi Madhiraju- July 10, 2024 0

Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company, has shared an interim update on a key study involving extended HyBryte treatment in patients with early-stage ... Read More

hVIVO engages in major phase 2b influeness drug study as exclusive UK clinical site

Pallavi Madhiraju- July 7, 2024 0

hVIVO plc (AIM & Euronext: HVO), a rapidly expanding specialist contract research organisation (CRO) renowned for its expertise in human challenge clinical trials for infectious ... Read More

Merck secures exclusive global license for opevesostat from Orion Corporation

Pallavi Madhiraju- July 7, 2024 0

Merck (NYSE: MRK), also known as MSD outside the United States and Canada, has enhanced its strategic position in the oncology market by securing an ... Read More

Johnson & Johnson’s CARVYKTI achieves significant milestone in multiple myeloma treatment

Pallavi Madhiraju- July 7, 2024 0

Johnson & Johnson (NYSE: JNJ) has recently announced encouraging outcomes from the second interim analysis of the Phase 3 CARTITUDE-4 study, which is pivotal in ... Read More

12345...830 / 75 Posts